Semnur Pharmaceuticals, Inc. (SMNRW) Financial Statements (2026 and earlier)

Company Profile

Business Address 960 SAN ANTONIO ROAD
PALO ALTO, CA 94303
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments20,00016,868204,464819,747
Cash and cash equivalent20,00016,868204,464819,747
Prepaid expense576,000 4,97688,089
Total current assets:596,00016,868209,440907,836
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization750,000   
Asset, held-in-trust  9,021,00550,477,96385,371,600
Total noncurrent assets:750,0009,021,00550,477,96385,371,600
TOTAL ASSETS:1,346,0009,037,87350,687,40386,279,436
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:6,651,00058,58618,8781,291,641
Accounts payable5,912,000   
Accrued liabilities739,00058,58618,878 
Other undisclosed accounts payable and accrued liabilities    1,291,641
Debt3,517,0001,350,292975,000 
Other undisclosed current liabilities  6,138,2064,610,102 
Total current liabilities:10,168,0007,547,0845,603,9801,291,641
Noncurrent Liabilities
Other undisclosed noncurrent liabilities11,928,0002,887,5002,887,5002,887,500
Total noncurrent liabilities:11,928,0002,887,5002,887,5002,887,500
Total liabilities:22,096,00010,434,5848,491,4804,179,141
Temporary equity, including noncontrolling interest  9,021,00550,477,96385,371,600
Equity
Equity, attributable to parent, including:(20,750,000)(10,417,716)(8,282,040)(3,271,305)
Preferred stock1,000   
Common stock23,000   
Additional paid in capital255,026,000   
Accumulated deficit(275,800,000)(10,417,973)(8,282,297)(3,271,562)
Other undisclosed equity, attributable to parent  257257257
Total equity:(20,750,000)(10,417,716)(8,282,040)(3,271,305)
TOTAL LIABILITIES AND EQUITY:1,346,0009,037,87350,687,40386,279,436

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Operating expenses(160,416,000)(1,649,106)(3,173,826) 
Operating loss:(160,416,000)(1,649,106)(3,173,826) 
Nonoperating income
(Investment Income, Nonoperating)		 1,578,0423,843,2711,221,600
Interest and debt expense (96,242)(36,909) 
Net income (loss):(160,416,000)(167,306)632,5361,221,600
Other undisclosed net loss attributable to parent    (1,640,990)
Net income (loss) attributable to parent:(160,416,000)(167,306)632,536(419,390)
Preferred stock dividends and other adjustments (1,968,370) (16,111,536)
Net income (loss) available to common stockholders, diluted:(160,416,000)(2,135,676)632,536(16,530,926)

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Net income (loss):(160,416,000)(167,306)632,5361,221,600
Comprehensive income (loss), net of tax, attributable to parent:(160,416,000)(167,306)632,5361,221,600

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios